Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.
DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.
Objective: To evaluate short-term safety and the effects on visual acuity and fluorescein angiography of single or multiple sessions of photodynamic therapy with verteporfin for choroidal neovascularization (CNV) not related to age-related macular degenera ...
OBJECTIVES: To evaluate safety and short-term visual acuity and fluorescein angiographic effects of photodynamic therapy (PDT) after retreatments with verteporfin for choroidal neovascularization (CNV) in age-related macular degeneration (AMD) that demonst ...
A device for the preventative photodynamic therapy of secondary cataract has been developed. Disturbance of the epithelial cells of the crystalline lens during the primary cataract surgery and/or their migration thereafter can frequently generate secondary ...
PURPOSE: We propose a feasibility study of new corneal topography technology with the aim of monitoring intraoperative corneal topography during excimer laser photorefractive keratectomy. The PAR system measures corneal topography with single grid projecti ...
The application of lasers in microsurgery and in particular in neurosurgery offers many advantages such as, e.g., hemostasis, no-touch (i.e. aseptic) procedures, and pinpoint accuracy. However, these advantages can often not be fully exploited since adequa ...
OBJECTIVE: To evaluate the safety and short-term visual and fluorescein angiographic effects of a single photodynamic therapy treatment with verteporfin with the use of different dosage regimens in patients with choroidal neovascularization (CNV) from age- ...
